Stocktoria
Amneal Pharmaceuticals, Inc. AMRX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2009-11-18
Amneal Pharmaceuticals, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 36.9% | 36.5% | 34.3% | 35.5% | 36.7% |
| Operating margin | 13.1% | 8.9% | 8.5% | -4.3% | 7.3% |
| Net margin | 2.4% | -4.2% | -3.5% | -12.2% | 0.6% |
| FCF margin | 8.9% | 8.7% | 12.6% | 0.8% | 9.3% |
| Return on assets | 2.0% | -3.3% | -2.4% | -7.1% | 0.3% |
| Return on equity | -101.0% | 106.7% | -419.7% | -90.7% | 3.6% |
| Debt / equity | -36.06× | -21.79× | 120.94× | 8.79× | 7.39× |
| Current ratio | 2.17 | 1.41 | 1.63 | 1.88 | 2.24 |
| Revenue growth | 8.0% | 16.7% | 8.2% | 5.7% | 5.1% |
Source: SEC EDGAR filings · CIK 0001723128 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.